Buy These 4 Stocks With Solid Net Profit Margin to Maximize Returns

Four companies—Catalyst Pharmaceuticals (CPRX), Gambling.com Group (GAMB), Orion Group Holdings (ORN), and BrainsWay Ltd. (BWAY)—have been identified as compelling investment opportunities based on their robust net profit margins, consistent earnings beats over the past four quarters, and recent upward revisions to 2025 EPS estimates. These selections align with a rigorous screening strategy emphasizing financial health, operational efficiency, and positive analyst sentiment, holding Zacks Ranks of 1 or 2 and solid VGM Scores, collectively suggesting further upside potential. The analysis underscores net profit margin as a critical indicator of a company's ability to convert sales into profit and manage costs effectively.

Analysis

The article presents a quantitative screening strategy focused on identifying companies with strong net profit margins, positive earnings per share (EPS) growth, and favorable analyst sentiment. Four companies are highlighted as passing this screen: Catalyst Pharmaceuticals (CPRX), Gambling.com Group (GAMB), Orion Group Holdings (ORN), and BrainsWay (BWAY). All four benefit from recent upward revisions to their 2025 EPS estimates and hold high Zacks Ranks (1 or 2) and strong VGM scores, signaling potential for further upside. Notably, CPRX, GAMB, and BWAY have demonstrated consistent execution by surpassing consensus earnings estimates in each of the last four quarters, with average surprises of 28.2%, 68.7%, and 153.3% respectively. This track record suggests robust operational control and financial health. However, Orion Group (ORN) presents a mixed profile; while it met the screening criteria and saw a minor upward EPS revision, its performance includes a significant earnings miss in the past year, leading to a large negative average surprise of -104.4%. This specific data point introduces a higher degree of execution risk for ORN compared to the other three highlighted firms.

Key Decisions for Investors

• Investors could consider Catalyst Pharmaceuticals (CPRX), Gambling.com (GAMB), and BrainsWay (BWAY) for further due diligence, as their consistent earnings beats and positive EPS revisions suggest strong operational momentum and fundamental health.
• Exercise particular caution with Orion Group (ORN); its inclusion is contradicted by a significant historical earnings miss, reflected in a -104.4% average surprise, which indicates higher potential volatility and execution risk.
• Given the analysis is based on a quantitative screen, it is critical to monitor upcoming quarterly results to validate that the highlighted high profit margins are sustainable and that the modest EPS estimate increases materialize into tangible growth.